Loading organizations...
§ Private Profile · North Chicago, IL, USA
Biotechnology company developing gut microbiome medicine, targeted diagnostics, and therapies to prevent and treat chronic diseases.
Based in Chicago, Illinois, 32 Biosciences is a biotechnology company founded in 2023 by Peter Farmakis, John Alverdy, Eugene Chang, and Joseph Pierre to develop diagnostic management tools and targeted microbiome-based interventions for chronic diseases. The firm operates through its primary subsidiaries, Covira and Gateway Biome, leveraging artificial intelligence and clinical research to commercialize therapeutics for conditions such as post-surgical infections. To advance its clinical pipeline, the enterprise has successfully secured $2,300,000 in grant funding alongside $1,650,000 in prior private capital. In late 2024, the company raised an additional $508,898 through a Republic crowdfunding campaign at a $31,250,000 valuation, preceding a planned $6,000,000 funding round in June 2025. Emerging from stealth mode in September 2024, the organization recently expanded its physical footprint by establishing research operations at the Rosalind Franklin University Innovation and Research Park.
32 Biosciences has raised $6.0M across 1 funding round.
32 Biosciences has raised $6.0M in total across 1 funding round.
32 Biosciences has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in June 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 10, 2025 | $6M Series A | — | — | Announced |
32 Biosciences has raised $6.0M in total across 1 funding round.